NLRP3 and hydrops fetalis: Dapagliflozin improves diabetic cardiomyopathy by inhibiting NLRP3 inflammasome activation, pyroptosis, and apoptosis while reducing pro-inflammatory factors in a TAC-induced HF model [295, 296].